Label: OXALIPLATIN injection, powder, lyophilized, for solution

  • NDC Code(s): 45963-611-53, 45963-611-59
  • Packager: Actavis Pharma, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated October 1, 2020

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use OXALIPLATIN FOR INJECTION safely and effectively. See full prescribing information for OXALIPLATIN FOR INJECTION.

    OXALIPLATIN for injection, for intravenous use
    Initial U.S. Approval: 2002

    WARNING: HYPERSENSITIVITY REACTIONS, INCLUDING ANAPHYLAXIS

    See full prescribing information for complete boxed warning.

    Serious and fatal hypersensitivity adverse reactions, including anaphylaxis, can occur with Oxaliplatin for Injection within minutes of administration and during any cycle. Oxaliplatin for Injection is contraindicated in patients with hypersensitivity reactions to oxaliplatin and other platinum-based drugs. Immediately and permanently discontinue Oxaliplatin for Injection for hypersensitivity reactions and administer appropriate treatment. (4, 5.1)  

    INDICATIONS AND USAGE

    Oxaliplatin for Injection is a platinum-based drug used in combination with infusional fluorouracil and leucovorin, which is indicated for:

    • adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. (1)
    • treatment of advanced colorectal cancer. (1)

    DOSAGE AND ADMINISTRATION

    • Administer Oxaliplatin for Injection 85 mg/m2 as an intravenous infusion over 120 minutes concurrently with leucovorin over 120 minutes in separate bags, followed by fluorouracil on Day 1 of each 14-day cycle. Administer fluorouracil and leucovorin on Day 2 as recommended. (2.1)
    • Adjuvant Treatment: Continue treatment for up to 12 cycles or unacceptable toxicity. (2.1)
    • Advanced Colorectal Cancer: Continue treatment until disease progression or unacceptable toxicity. (2.1)

    DOSAGE FORMS AND STRENGTHS

    Single-dose vials of 50 mg or 100 mg oxaliplatin as a sterile, preservative-free lyophilized powder for reconstitution. (3)

    CONTRAINDICATIONS

    • History of hypersensitivity reaction to Oxaliplatin for Injection or other platinum-based drugs. (4, 5.1)

    WARNINGS AND PRECAUTIONS

    • Peripheral Sensory Neuropathy: Acute and delayed neuropathy can occur. Avoid topical application of ice. Reduce the dose or permanently discontinue Oxaliplatin for Injection as recommended. (5.2)
    • Severe Myelosuppression: Delay Oxaliplatin for Injection until neutrophils are greater than or equal to 1.5 × 109/L and platelets are greater than or equal to 75 × 109/L. Withhold Oxaliplatin for Injection for sepsis or septic shock. Dose reduce after recovery from grade 4 neutropenia, febrile neutropenia, or grade 3 to 4 thrombocytopenia as recommended. (5.3)
    • Posterior Reversible Encephalopathy Syndrome (PRES): Permanently discontinue Oxaliplatin for Injection in patients who develop PRES. (5.4)
    • Pulmonary Toxicity: Withhold Oxaliplatin for Injection until investigation excludes interstitial lung disease or pulmonary fibrosis. (5.5)
    • Hepatotoxicity: Monitor liver function tests at baseline, before each subsequent cycle, and as clinically indicated. (5.6)
    • QT Interval Prolongation: Avoid in patients with congenital long QT syndrome. Monitor electrocardiograms in patients with congestive heart failure, bradyarrhythmias, and electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Correct electrolyte abnormalities prior to initiating Oxaliplatin for Injection and periodically during treatment. (5.7)
    • Rhabdomyolysis: Permanently discontinue Oxaliplatin for Injection if rhabdomyolysis occurs. (5.8)
    • Hemorrhage: Increase frequency of monitoring in patients who are receiving Oxaliplatin for Injection with fluorouracil/leucovorin and oral anticoagulants (5.9)
    • Embryo-Fetal Toxicity: Can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise males and females of reproductive potential to use an effective method of contraception. (5.10, 8.1, 8.3)

    ADVERSE REACTIONS

    Most common adverse reactions (incidence greater than or equal to 40%) were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue, and stomatitis.  (6.1)

    To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    USE IN SPECIFIC POPULATIONS

    • Lactation: Advise not to breastfeed.

    See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

    Revised: 10/2020

  • Table of Contents

    FULL PRESCRIBING INFORMATION: CONTENTS*

    WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS

    1  INDICATIONS AND USAGE

    2  DOSAGE AND ADMINISTRATION

    2.1 Recommended Dosage

    2.2 Dose Modifications for Adverse Reactions

    2.3 Dose Modifications for Patients with Renal Impairment

    2.4 Preparation and Administration

    3  DOSAGE FORMS AND STRENGTHS

    4  CONTRAINDICATIONS

    5  WARNINGS AND PRECAUTIONS

    5.1 Hypersensitivity Reactions 

    5.2 Peripheral Sensory Neuropathy 

    5.3 Severe Myelosuppression

    5.4 Posterior Reversible Encephalopathy Syndrome 

    5.5 Pulmonary Toxicity 

    5.6 Hepatotoxicity

    5.7 QT Interval Prolongation and Ventricular Arrhythmias

    5.8 Rhabdomyolysis 

    5.9 Hemorrhage 

    5.10 Embryo-Fetal Toxicity

    6  ADVERSE REACTIONS

    6.1 Clinical Trials Experience 

    6.2 Postmarketing Experience 

    7  DRUG INTERACTIONS

    7.1 Drugs that Prolong the QT Interval

    7.2 Use with Nephrotoxic Products

    7.3 Use with Anticoagulants

    8  USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    8.2 Lactation

    8.3 Females and Males of Reproductive Potential 

    8.4 Pediatric Use

    8.5 Geriatric Use

    8.6 Patients with Renal Impairment 

    10  OVERDOSAGE

    11  DESCRIPTION

    12  CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    12.2 Pharmacodynamics

    12.3 Pharmacokinetics 

    13  NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 

    14  CLINICAL STUDIES

    14.1 Adjuvant Treatment with Oxaliplatin for Injection in Combination with Fluorouracil and Leucovorin

    14.2 Previously Untreated Advanced Colorectal Cancer 

    14.3 Previously Treated Advanced Colorectal Cancer  

    15  REFERENCES

    16  HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How Supplied

    16.2 Storage

    17  PATIENT COUNSELING INFORMATION

    *
    Sections or subsections omitted from the full prescribing information are not listed.
  • BOXED WARNING (What is this?)

    WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS

    Serious and fatal hypersensitivity adverse reactions, including anaphylaxis, can occur with Oxaliplatin for Injection within minutes of administration and during any cycle. Oxaliplatin for Injection is contraindicated in patients with hypersensitivity reactions to oxaliplatin and other platinum-based drugs [see Contraindications (4)]. Immediately and permanently discontinue Oxaliplatin for Injection for hypersensitivity reactions and administer appropriate treatment for management of the hypersensitivity reaction [see Warnings and Precautions (5.1)].

  • 1  INDICATIONS AND USAGE

    Oxaliplatin for Injection, in combination with infusional fluorouracil and leucovorin, is indicated for:

    • adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
    • treatment of advanced colorectal cancer.
  • 2  DOSAGE AND ADMINISTRATION

    2.1 Recommended Dosage

    Administer Oxaliplatin for Injection in combination with fluorouracil and leucovorin every 2 weeks.

    • For adjuvant treatment, continue treatment for up to 12 cycles or unacceptable toxicity.
    • For advanced colorectal cancer, continue treatment until disease progression or unacceptable toxicity.

    Day 1

    Administer Oxaliplatin for Injection 85 mg/m2 as an intravenous infusion over 120 minutes and leucovorin 200 mg/m2 as an intravenous infusion over 120 minutes at the same time in separate bags, followed by fluorouracil 400 mg/m2 as intravenous bolus over 2 to 4 minutes, followed by fluorouracil 600 mg/m2 as a 22-hour continuous infusion.

    Day 2

    Administer leucovorin 200 mg/m2 as an intravenous infusion over 120 minutes, followed by fluorouracil 400 mg/m2 as intravenous bolus over 2 to 4 minutes, followed by fluorouracil 600 mg/m2 as a 22-hour continuous infusion.

    Refer to the prescribing information for fluorouracil and leucovorin for additional information.

    2.2 Dose Modifications for Adverse Reactions

    Prolongation of infusion time for Oxaliplatin for Injection from 2 hours to 6 hours may mitigate acute toxicities, such as non-life threatening infusion-related reactions.

    Permanently discontinue Oxaliplatin for Injection for any of the following:

    • Hypersensitivity Reactions [see Warnings and Precautions (5.1)]
    • Posterior reversible encephalopathy syndrome (PRES) [see Warnings and Precautions (5.4)]
    • Confirmed interstitial lung disease or pulmonary fibrosis [see Warnings and Precautions (5.5)] Rhabdomyolysis [see Warnings and Precautions (5.8)]

    Refer to the fluorouracil and leucovorin prescribing information for dosage modifications for adverse reactions.

    Dosage Modifications for Adjuvant Treatment

    Dosage modifications for adverse reactions for adjuvant treatment are presented in Table 1.

    Table 1: Dosage Modifications for Adjuvant Treatment in Patients with Stage III Colon Cancer
    Adverse Reactions Severity  Oxaliplatin for Injection Dosage 
       Modifications
     Peripheral Sensory Neuropathy  Persistent Grade 2 Consider reducing Oxaliplatin for 
     [see Warnings and Precautions (5.2)]   Injection dose to 75 mg/m2
      Persistent Grade 3 Consider discontinuing Oxaliplatin for
       Injection. 
      Grade 4  Discontinue Oxaliplatin for Injection.
      Grade 4 neutropenia or Delay the next dose until neutrophils 
      febrile neutropenia  greater than or equal to 1.5 × 109/L and 
       platelets greater than or equal to 
     Myelosuppression   75 × 109/L. 
     [see Warnings and Precautions (5.3), Grade 3 to 4  
     Adverse Reactions (6.1)] thrombocytopenia 
       Reduce Oxaliplatin for Injection dose to 75 
       mg/m2.
       After recovery, reduce Oxaliplatin for
     Gastrointestinal Adverse Reactions   Injection dose to 75 mg/m2 along with a 
     [see Adverse Reactions (6.1)]  Grade 3 to 4  dose reduction of fluorouracil to 300 
       mg/m2 as an intravenous bolus and 500
       mg/m2 as a 22-hour continuous infusion.

    Dosage Modifications for Advanced Colorectal Cancer

    Dosage modifications for adverse reactions for advanced colorectal cancer are presented in Table 2.

    Table 2: Dosage Modifications for Advanced Colorectal Cancer
     Adverse Reactions Severity  Oxaliplatin for Injection Dosage 
       Modifications
      Persistent Grade 2Consider reducing Oxaliplatin for  
     Neuropathy   Injection dose to 65 mg/m2
     [see Warnings and Precautions (5.2)]  Persistent Grade 3 Consider discontinuing Oxaliplatin for 
       Injection. 
      Grade 4  Discontinue Oxaliplatin for Injection.
      Grade 4 neutropenia  Delay the next dose until neutrophils 
      or febrile neutropenia  greater than or equal to 1.5 × 109/L and 
     Myelosuppression  platelets greater than or equal to 
     [see Warnings and Precautions (5.3) Grade 3 to 4  75 × 109/L.
     Adverse Reactions (6.1)] thrombocytopenia  
       Reduce Oxaliplatin for Injection dose to 65 
       mg/m2
       After recovery, reduce Oxaliplatin for
       Injection dose to 65 mg/m2 along with a
     Gastrointestinal Adverse Reactions  Grade 3 to 4 dose reduction of fluorouracil to 
     [see Adverse Reactions (6.1)]   300 mg/m2 as an intravenous bolus and 
       500 mg/m2 as a 22-hour continuous
       infusion. 

    2.3 Dose Modifications for Patients with Renal Impairment

    In patients with severe renal impairment (creatinine clearance [CLcr] less than 30 mL/min, calculated by the Cockcroft-Gault equation), reduce the Oxaliplatin for Injection dose to 65 mg/m[see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].

    2.4 Preparation and Administration

    Powder for solution for infusion

    Reconstitution or final dilution must never be performed with a sodium chloride solution or other chloride containing solutions.

    The lyophilized powder is reconstituted by adding 10 mL (for the 50 mg vial) or 20 mL (for the 100 mg vial) of Water for Injection, USP or 5% Dextrose Injection, USP. Do not administer the reconstituted solution without further dilution. The reconstituted solution must be further diluted in an infusion solution of 250 to 500 mL of 5% Dextrose Injection, USP. After reconstitution in the original vial, the solution may be stored up to 24 hours under refrigeration [2° to 8°C (36° to 46°F)]. After final dilution with 250 to 500 mL of 5% Dextrose Injection, USP, the shelf life is 6 hours at room temperature [20° to 25°C (68° to 77°F)] or up to 24 hours under refrigeration [2° to 8°C (36° to 46°F)].

    • Oxaliplatin for Injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.1
    • Visually inspect for particulate matter and discoloration prior to administration and discard if present.
    • Do not mix Oxaliplatin for Injection or administer Oxaliplatin for Injection through the same infusion line concurrently with alkaline medications or media (such as basic solutions of fluorouracil).
    • Flush the infusion line with 5% Dextrose Injection, USP prior to administration of any concomitant medication.
    • Do not use needles or intravenous administration sets containing aluminum parts for the preparation or mixing of Oxaliplatin for Injection. Aluminum has been reported to cause degradation of platinum compounds.
    • Administer Oxaliplatin for Injection as an intravenous infusion over 120 minutes concurrently with leucovorin over 120 minutes in separate bags.
  • 3  DOSAGE FORMS AND STRENGTHS

    Oxaliplatin for Injection, USP is supplied in single-dose vials containing 50 mg or 100 mg of oxaliplatin, USP as a sterile, preservative-free lyophilized powder for reconstitution.

  • 4  CONTRAINDICATIONS

    Oxaliplatin for Injection is contraindicated in patients with a history of a hypersensitivity reaction to Oxaliplatin for Injection or other platinum-based drugs. Reactions have included anaphylaxis [see Warnings and Precautions (5.1)].

  • 5  WARNINGS AND PRECAUTIONS

    5.1 Hypersensitivity Reactions 

    Serious and fatal hypersensitivity reactions, including anaphylaxis, can occur with Oxaliplatin for Injection within minutes of administration and during any cycle. Grade 3 to 4 hypersensitivity reactions, including anaphylaxis, occurred in 2% to 3% of patients with colon cancer who received Oxaliplatin for Injection. Hypersensitivity reactions, including rash, urticaria, erythema, pruritus, and, rarely, bronchospasm and hypotension, were similar in nature and severity to those reported with other platinum-based drugs.

    Oxaliplatin for Injection is contraindicated in patients with hypersensitivity reactions to platinum-based drugs [see Contraindications (4)]. Immediately and permanently discontinue Oxaliplatin for Injection for hypersensitivity reactions and administer appropriate treatment for management of hypersensitivity reactions.

    5.2 Peripheral Sensory Neuropathy 

    Oxaliplatin for Injection can cause acute and delayed neuropathy. Reduce the dose or permanently discontinue Oxaliplatin for Injection for persistent neurosensory reactions based on the severity of the adverse reaction [see Dosage and Administration (2.3)].

    Acute Neuropathy

    Acute neuropathy typically presents as a reversible, primarily peripheral sensory neuropathy that occurs within hours or 2 days following a dose, resolves within 14 days, and frequently recurs with further dosing. The symptoms can be precipitated or exacerbated by exposure to cold temperature or cold objects and they usually present as transient paresthesia, dysesthesia and hypoesthesia in the hands, feet, perioral area, or throat. Jaw spasm, abnormal tongue sensation, dysarthria, eye pain, and a feeling of chest pressure have also been observed. The acute, reversible pattern of sensory neuropathy was observed in about 56% of patients who received Oxaliplatin for Injection with fluorouracil/leucovorin. In any individual cycle, acute neuropathy occurred in approximately 30% of patients. For grade 3 peripheral sensory neuropathy, the median time to onset was 9 cycles for adjuvant treatment and 6 cycles for previously treated advanced colorectal cancer.

    An acute syndrome of pharyngolaryngeal dysesthesia occurred in 1% to 2% (grade 3 to 4) of patients previously untreated for advanced colorectal cancer. Subjective sensations of dysphagia or dyspnea, without any laryngospasm or bronchospasm (no stridor or wheezing) occurred in patients previously treated for advanced colorectal cancer.

    Avoid topical application of ice for mucositis prophylaxis or other conditions, because cold temperature can exacerbate acute neurological symptoms.

    Delayed Neuropathy

    Delayed neuropathy typically presents as a persistent (greater than 14 days), primarily peripheral sensory neuropathy that is usually characterized by paresthesias, dysesthesias, and hypoesthesias, but may also include deficits in proprioception that can interfere with daily activities (e.g., writing, buttoning, swallowing, and difficulty walking from impaired proprioception). These forms of neuropathy occurred in 48% of patients receiving Oxaliplatin for Injection. Delayed neuropathy can occur without any prior acute neuropathy. Most patients (80%) who developed grade 3 persistent neuropathy progressed from prior grade 1 or 2 reactions. These symptoms may improve in some patients upon discontinuation of Oxaliplatin for Injection.

    Adjuvant Treatment

    In the adjuvant treatment trial, neuropathy was graded using NCI CTC, version 1 as summarized in Table 3.

    Table 3: Grading for Neuropathy in Adjuvant Treatment Trial
     Grade Definition
     0 No change or none
     1 Mild paresthesias, loss of deep tendon reflexes
     2 Mild or moderate objective sensory loss, moderate paresthesias
     3 Severe objective sensory loss or paresthesias that interfere with function
     4 Not applicable

    Peripheral sensory neuropathy occurred in 92% of patients (all grades), including 13% of patients (grade 3) who received Oxaliplatin for Injection with fluorouracil/leucovorin. At the 28-day follow-up after the last treatment cycle, 60% of patients had any grade (grade 1=40%, grade 2=16%, grade 3=5%) peripheral sensory neuropathy, decreasing to 39% at 6 months of follow-up (grade 1=31%, grade 2=7%, grade 3=1%) and 21% at 18 months of follow-up (grade 1=17%, grade 2=3%, grade 3=1%).

    Advanced Colorectal Cancer

    In the advanced colorectal cancer trials, neuropathy was graded using the neurotoxicity scale summarized in Table 4.

    Table 4: Grading for Neuropathy in Advanced Colorectal Cancer Trials
     Grade Definition
     1 Resolved and did not interfere with functioning
     2 Interfered with function but not daily activities
     3 Pain or functional impairment that interfered with daily activities
     4 Persistent impairment that is disabling or life-threatening

    Neuropathy occurred in 82% (all grades) of patients previously untreated for advanced colorectal cancer, including 19% grade 3 to 4; and in 74% (all grades) of patients previously treated for advanced colorectal cancer, including 7% grade 3 to 4.

    5.3 Severe Myelosuppression

    Grade 3 or 4 neutropenia occurred in 41% to 44% of patients with colorectal cancer who received Oxaliplatin for Injection with flurouracil/leucovorin. Sepsis, neutropenic sepsis and septic shock, including fatal outcomes, occurred in patients who received Oxaliplatin for Injection [see Adverse Reactions (6.1, 6.2)].

    Grade 3 or 4 thrombocytopenia occurred in 2% to 5% of patients with colorectal cancer who received Oxaliplatin for Injection with fluorouracil/leucovorin.

    Monitor complete blood cell count at baseline, before each subsequent cycle and as clinically indicated. Delay Oxaliplatin for Injection until neutrophils are greater than or equal to 1.5 × 109/L and platelets are greater than or equal to 75 × 109/L. Withhold Oxaliplatin for Injection for sepsis or septic shock. Dose reduce Oxaliplatin for Injection after recovery from grade 4 neutropenia, febrile neutropenia or grade 3 to 4 thrombocytopenia as recommended [see Dosage and Administration (2.2)].

    5.4 Posterior Reversible Encephalopathy Syndrome 

    PRES occurred in less than 0.1% of patients across clinical trials [see Adverse Reactions (6.1)]. Signs and symptoms of PRES can include headache, altered mental functioning, seizures, abnormal vision from blurriness to blindness, associated or not with hypertension. Confirm the diagnosis of PRES with magnetic resonance imaging. Permanently discontinue Oxaliplatin for Injection in patients who develop PRES.

    5.5 Pulmonary Toxicity 

    Oxaliplatin for Injection has been associated with pulmonary fibrosis (less than 1% of patients), which may be fatal [see Adverse Reactions (6.1)].

    In the adjuvant treatment trial, the combined incidence of cough and dyspnea was 7.4% (any grade), including less than 1% (grade 3) in the Oxaliplatin for Injection arm. One patient died from eosinophilic pneumonia in the Oxaliplatin for Injection arm.

    In the previously untreated advanced colorectal cancer trial, the combined incidence of cough, dyspnea and hypoxia was 43% (any grade), including 7% (grade 3 to 4) in the Oxaliplatin for Injection with fluorouracil/leucovorin arm.

    In case of unexplained respiratory symptoms, such as non-productive cough, dyspnea, crackles, or radiological pulmonary infiltrates, withhold Oxaliplatin for Injection until further pulmonary investigation excludes interstitial lung disease or pulmonary fibrosis. Permanently discontinue Oxaliplatin for Injection for confirmed interstitial lung disease or pulmonary fibrosis.

    5.6 Hepatotoxicity

    In the adjuvant treatment trial, increased transaminases (57% vs 34%) and alkaline phosphatase (42% vs 20%) occurred more commonly in the Oxaliplatin for Injection arm than in the fluorouracil/leucovorin arm [see Adverse Reactions (6.1)]. The incidence of increased bilirubin was similar on both arms. Changes noted on liver biopsies include: peliosis, nodular regenerative hyperplasia or sinusoidal alterations, perisinusoidal fibrosis, and veno-occlusive lesions. Consider evaluating patients who develop abnormal liver tests or portal hypertension which cannot be explained by liver metastases, for hepatic vascular disorders. Monitor liver function tests at baseline, before each subsequent cycle and as clinically indicated.

    5.7 QT Interval Prolongation and Ventricular Arrhythmias

    QT prolongation and ventricular arrhythmias, including fatal torsade de pointes, have been reported with Oxaliplatin for Injection [see Adverse Reactions (6.2)].

    Avoid Oxaliplatin for Injection in patients with congenital long QT syndrome. Monitor electrocardiograms (ECG) in patients with congestive heart failure, bradyarrhythmias, and electrolyte abnormalities and in patients taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics [see Drug Interactions (7.1)]. Monitor and correct electrolyte abnormalities prior to initiating Oxaliplatin for Injection and periodically during treatment. 

    5.8 Rhabdomyolysis 

    Rhabdomyolysis, including fatal cases, has been reported with Oxaliplatin for Injection [see Adverse Reactions (6.2)]. Permanently discontinue Oxaliplatin for Injection for any signs or symptoms of rhabdomyolysis.

    5.9 Hemorrhage 

    The incidence of hemorrhage in clinical trials was higher on the Oxaliplatin for Injection combination arm compared to the fluorouracil/leucovorin arm. These reactions included gastrointestinal bleeding, hematuria, and epistaxis. In the adjuvant treatment trial, 2 patients died from intracerebral hemorrhage [see Adverse Reactions (6.1)].

    Prolonged prothrombin time and INR occasionally associated with hemorrhage have been reported in patients who received Oxaliplatin for Injection with fluorouracil/leucovorin while on anticoagulants [see Adverse Reactions (6.2)]. Increase frequency of monitoring in patients who are receiving Oxaliplatin for Injection with fluorouracil/leucovorin and oral anticoagulants [see Drug Interactions (7.3)].

    Thrombocytopenia and immune-mediated thrombocytopenia have been observed with Oxaliplatin for Injection. Rapid onset of thrombocytopenia and greater risk of bleeding have been observed in immune-mediated thrombocytopenia. In this case, consider discontinuing Oxaliplatin for Injection.

    5.10 Embryo-Fetal Toxicity

    Based on findings from animal studies and its mechanism of action, Oxaliplatin for Injection can cause fetal harm when administered to a pregnant woman. The available human data do not establish the presence or absence of major birth defects or miscarriage related to the use of Oxaliplatin for Injection. Reproductive toxicity studies demonstrated adverse effects on embryo-fetal development in rats at maternal doses that were below the recommended human dose based on body surface area. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Oxaliplatin for Injection and for at least 9 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with Oxaliplatin for Injection and for 6 months after the final dose [see Use in Specific Populations (8.1, 8.3)].

  • 6  ADVERSE REACTIONS

    The following clinically significant adverse reactions are described elsewhere in labeling:

    • Hypersensitivity Reactions [see Warnings and Precautions (5.1)]
    • Peripheral Sensory Neuropathy [see Warnings and Precautions (5.2)]
    • Severe Myelosuppression [see Warnings and Precautions (5.3)]
    • Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions (5.4)]
    • Pulmonary Toxicity [see Warnings and Precautions (5.5)]
    • Hepatotoxicity [see Warnings and Precautions (5.6)]
    • QT Interval Prolongation and Ventricular Arrhythmias [see Warnings and Precautions (5.7)]
    • Rhabdomyolysis [see Warnings and Precautions (5.8)]
    •  Hemorrhage [see Warnings and Precautions (5.9)]

    6.1 Clinical Trials Experience 

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    More than 1100 patients with stage II or III colon cancer and more than 4,000 patients with advanced colorectal cancer were treated in trials with Oxaliplatin for Injection. The most common adverse reactions in patients with stage II or III colon cancer receiving adjuvant treatment were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue and stomatitis. The most common adverse reactions in previously untreated and treated patients with advanced colorectal cancer were peripheral sensory neuropathies, fatigue, neutropenia, nausea, emesis, and diarrhea.

    Adjuvant Treatment

    The safety of Oxaliplatin for Injection in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in patients with stage II or III colon cancer, who had undergone complete resection of the primary tumor in the adjuvant treatment trial [see Clinical Studies (14.1)].

    Fatal adverse reactions in patients who received Oxaliplatin for Injection in the combination arm included sepsis/neutropenic sepsis (n=3), intracerebral hemorrhage (n=2) and eosinophilic pneumonia (n=1).

    Thromboembolic events occurred in 6% (grade 3 to 4, 1.2%) of patients in the Oxaliplatin for Injection arm.

    Grade 3 or 4 adverse reactions occurred in 70% of patients in the Oxaliplatin for Injection arm. 

    Grade 3 to 4 gastrointestinal bleeding occurred in 0.2% of patients. Febrile neutropenia occurred in 0.7% and documented infection with concomitant grade 3 to 4 neutropenia occurred in 1.1%.

    Discontinuation due to an adverse reaction occurred in 15% of the patients in the Oxaliplatin for Injection arm.

    Tables 5, 6, and 7 summarize the adverse reactions reported in patients with colon cancer receiving adjuvant treatment.

    Table 5: Adverse Reactions Reported in Patients with Colon Cancer Receiving Adjuvant Treatment (greater than or equal to 5% of all patients and with greater than or equal to 1% grade 3 to 4)
     Adverse Reaction* Oxaliplatin + FU/LV FU/LV
     * Event coded in WHO-ART dictionary
      Includes thrombosis related to the catheter
      N=1108 N=1111
        All Grades  Grade 3 to 4  All Grades  Grade 3 to 4
      (%) (%) (%) (%)
     Neurology    
     Peripheral Sensory Neuropathy92 12 16 <1
     Gastrointestinal    
     Nausea7461 
     Diarrhea 5611 48 
     Vomiting47 24 
     Stomatitis42 40 
     Anorexia13  <1
     Constitutional Symptoms/Pain    
     Fatigue 4438 
     Abdominal Pain 1817 
     Dermatology/Skin    
     Skin Disorder 3236 
     Injection Site Reaction 1110 
     Fever/Infection    
     Fever 2712 
     Infection25 25 
     Allergy/Immunology
     Allergic Reaction 10 3 2 <1
    Table 6: Adverse Reactions Reported in Patients with Colon Cancer Receiving Adjuvant Treatment (greater than or equal to 5% of all patients but with less than 1% grade 3 to 4)
      Oxaliplatin + FU/LV FU/LV
      N=1108 N=1111
    Adverse Reaction* All Grades (%) All Grades (%)
     Dermatology/Skin
     Alopecia 30 28
     Gastrointestinal
     Constipation 2219 
     Taste Perversion 12 8
     Dyspepsia   8  5
     Constitutional Symptoms/Pain/Ocular/Visual
     Epistaxis 16 12
     Weight Increase 10 10 
     Conjunctivitis 9 15
     Headache 7 5
     Dyspnea 5 3
     Pain 5 5
     Abnormal Lacrimation  4  12
     Neurology
     Sensory Disturbance 8 1
    Allergy/Immunology
     Rhinitis6 8
      * Event coded in WHO-ART dictionary
      No complete alopecia was reported.

    In females, the following grade 3 to 4 adverse reactions were more frequent: diarrhea, fatigue, neutropenia, nausea, and vomiting.

    In patients greater than or equal to 65 years old, the incidence of grade 3 to 4 diarrhea and neutropenia was higher than in younger adults.

    Clinically relevant adverse reactions were reported in greater than or equal to 2% and less than 5% of the patients in the Oxaliplatin for Injection arm (listed in decreasing order of frequency) were pain, leukopenia, weight loss, and cough.

    Table 7: Laboratory-Related Adverse Reactions Occurring in ≥5% of Patients with Colon Cancer Receiving Adjuvant Treatment
    Laboratory-Related Adverse Reaction Oxaliplatin with FU/LV FU/LV
     N=1108N=1111 
     All GradesGrades 3 to 4All GradesGrades 3 to 4
    (%)(%)(%)(%)
    Hematology  
    Neutropenia7941405
    Thrombocytopenia77219<1
     Anemia 7667 <1 
     Hepatic
     Increased    
     Transaminases  57 234 
     Increased Alkaline    
     Phosphatase 42  <120  <1 
     Hyperbilirubinemia2020 

    Previously Untreated Advanced Colorectal Cancer

    The safety of Oxaliplatin for Injection in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in a randomized trial of patients with previously untreated advanced colorectal cancer [see Clinical Studies (14.2)]. The adverse reaction profile in this trial was similar to that seen in other trials.

    Tables 8, 9, and 10 summarize the adverse reactions reported in the previously untreated advanced colorectal cancer trial.

    Table 8: Adverse Reactions Reported in Patients in the Previously Untreated Advanced Colorectal Cancer Clinical Trial (greater than or equal to 5% of all patients and with greater than or equal to 1% grade 3 to 4)
      Oxaliplatin + Irinotecan +Oxaliplatin 
     FU/LVFU/LV Irinotecan 
    Adverse Reaction*N=259N=256N=258
     AllGradeAllGradeAllGrade
     Grades3 to 4Grades3 to 4Grades3 to 4
    (%)(%)(%)(%)(%)(%)
     Neurology
     Neuropathy  8219 18 69 
     Paresthesias 77 18 16 62 
     Pharyngo-laryngeal       
     Dysesthesias 38 28 
     Neuro-sensory 12
     Neuro NOS†  1
     Gastrointestinal
     Nausea71 67 15 83 19 
     Diarrhea56 12 65 29 76 25 
     Vomiting41 43 13 64 23 
     Stomatitis38 25 19 
     Anorexia35 25 27 5
     Constipation 324272212
     Diarrhea-colostomy 132167163
     Gastrointestinal NOS524232
     Constitutional Symptoms/Pain/Ocular/Visual
     Fatigue70758116616
     Abdominal Pain 2983173910
     Myalgia 1426092
     Pain 715161
     Abnormal Vision502161
     Neuralgia500021
     Pulmonary      
     Cough351252171
     Dyspnea 187143112
     Hiccups 512032
     Hepatic/Metabolic/Laboratory/Renal
     Hyperglycemia142113123
     Hypokalemia1137462
     Dehydration951611147
     Hypoalbuminemia 805291
     Hyponatremia 827441
     Urinary Frequency 512131
     Hematology/Infection 
     Infection Normal ANC 1045172
     Infection Low ANC 88121198
     Lymphopenia624152
     Febrile Neutropenia4415141211
     Dermatology/Skin
     Hand/Foot Syndrome712110
     Injection Site Reaction601041
     Cardiovascular
     Thrombosis656633
     Hypotension 536343
     * Event coded in WHO-ART dictionary
      Not otherwise specified
     Absolute neutrophil count
    Table 9: Adverse Reactions Reported in Patients in the Previously Untreated Advanced Colorectal Cancer Clinical Trial (greater than or equal to 5% of all patients but with less than 1% grade 3 to 4)
     Oxaliplatin Irinotecan Oxaliplatin +
      5-FU/LV 5-FU/LVIrinotecan 
      N=259 N=256 N=258
    Adverse Reaction*   All Grades  All Grades All Grades 
       (%)  (%)  (%)
    Dermatology/Skin 
     Alopecia 38 4467 
     Flushing 7
     Pruritus 6
     Dry Skin 6
    Hematology/Infection 
     Fever Normal ANC‡  16
    Cardiovascular 
     Edema 1513 10 
    Gastrointestinal 
     Taste Perversion 14
     Dyspepsia 12
     Flatulence 9
     Mouth Dryness53
     Constitutional Symptoms/Pain/Ocular/Visual
     Headache 13
     Weight Loss 1111 
     Epistaxis10 
     Tearing 9
     Rigors 8
    Dysphasia 5
     Sweating 512 
     Arthralgia 5
     Neurology 
     Insomnia13 11 
     Depression 9
     Dizziness 810 
     Anxiety 5
     Allergy/Immunology
     Rash 11
     Rhinitis Allergic 10
     Hepatic/Metabolic/Laboratory/Renal
     Hypocalcemia 7
     Elevated Creatinine 4
     * Event coded in WHO-ART dictionary
      No complete alopecia was reported.
     Absolute neutrophil count

    Clinically relevant adverse reactions that occurred in greater than or equal to 2% and less than 5% of the patients in the Oxaliplatin for Injection and fluorouracil/leucovorin combination arm (listed in decreasing order of frequency) were: metabolic, pneumonitis, catheter infection, vertigo, prothrombin time, pulmonary, rectal bleeding, dysuria, nail changes, chest pain, rectal pain, syncope, hypertension, hypoxia, unknown infection, bone pain, pigmentation changes, and urticaria.

    Table 10: Laboratory-Related Adverse Reactions Occurring in ≥5% of Patients in the Previously Untreated Advanced Colorectal Cancer Trial

    Oxaliplatin andIrinotecan andOxaliplatin and
     Laboratory-RelatedFU/LVFU/LVIrinotecan
    Adverse ReactionN=259N=256N=258
    AllGradesAllGradesAllGrades
    Grades3 to 4Grades3 to 4Grades3 to 4
    (%)(%)(%)(%)(%)(%)
    Hematology
    Leukopenia852084237624
    Neutropenia815377447136
    Thrombocytopenia 715262444
    Anemia 273284253
    Hepatic
    Increased AST*
    17121111
    Increased Alkaline       
    Phosphatase16080142
    Hyperbilirubinemia 613132
    Increased ALT612052
    * Aspartate transaminase

    Alanine transaminase

    Previously Treated Advanced Colorectal Cancer

    The safety of Oxaliplatin for Injection in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in a randomized trial in patients with refractory and relapsed colorectal cancer [see Clinical Studies (14.3)]. The adverse reaction profile in this trial was similar to that seen in other trials.

    Three patients who received Oxaliplatin for Injection in the combination arm experienced fatal adverse reactions: gastrointestinal bleeding and dehydration.

    Grade 3 and 4 neutropenia were reported in 27% and 17% of patients, respectively, in the Oxaliplatin for Injection with fluorouracil/leucovorin combination arm. Grade 3 to 4 increased serum creatinine occurred in 1% of patients in the Oxaliplatin for Injection with combination fluorouracil/leucovorin arm.

    Thirteen percent of patients in the Oxaliplatin for Injection with fluorouracil/leucovorin combination arm discontinued treatment; the most frequent reasons were gastrointestinal adverse reactions, hematologic adverse reactions and neuropathies.

    Tables 11, 12, and 13 summarize the adverse reactions reported in the previously treated advanced colorectal cancer trial.

    Table 11: Adverse Reactions Reported in Patients in the Previously Treated Advanced Colorectal Cancer Trial (greater than or equal to 5% of all patients and with greater than or equal to 1% grade 3 to 4)
      Oxaliplatin +   
      FU/LV Oxaliplatin FU/LV
     Adverse Reaction*N=150  N=153 N=142
      All Grade All Grade All Grade 
      Grades 3 to 4 Grades 3 to 4 Grades 3 to 4
    Neurology
     Neuropathy74 76 17 

     Acute

    5665 10 

     Persistent

     48 43 
     Constitutional Symptoms/Pain 
     Fatigue
     6861952 6
     Back Pain 19110164
     Pain 1514 
     Gastrointestinal
     Diarrhea 6711 46 44 
     Nausea 6511 64 59 
     Vomiting 4037 27 
     Stomatitis 3714 32 
     Abdominal Pain 3331 31 
     Anorexia 2920 20 
     Gastroesophageal Reflux 5
     Hematology/Infection
     Fever 2925 23 
     Febrile Neutropenia 6
     Cardiovascular 
     Dyspnea 2013 11 
     Coughing 1911 
     Edema 1510 13 
     Thromboembolism 9
     Chest Pain 8 1
     Dermatology/Skin
     Injection Site Reaction 10
     Hepatic/Metabolic/Laboratory/Renal
     Hypokalemia 9
     Dehydration 8
     * Event coded in WHO-ART dictionary
    Table 12: Adverse Reactions Reported in Patients in the Previously Treated Advanced Colorectal Cancer Clinical Trial (greater than or equal to 5% of all patients but with less than 1% grade 3 to 4)
      Oxaliplatin +
     FU/LV Oxaliplatin5-FU/LV 
    Adverse Reaction*  N=150 N=153 N=142
     All Grades All Grades All Grades
     (%) (%) (%)
     Gastrointestinal
     Constipation 3231 23 
     Dyspepsia 1410 
     Taste Perversion 13
     Mucositis 710 
     Flatulence 5
     Constitutional Symptoms/Pain/Ocular/Visual
     Headache17 13 
     Arthralgia10 10 
     Epistaxis 9
     Abnormal Lacrimation
     Rigors 7
     Allergy/Immunology
     Rhinitis15 
     Allergic Reaction10 
     Rash 9
     Neurology
     Dizziness 13
     Insomnia11 
     Dermatology/Skin
     Hand-Foot Syndrome 1113 
     Flushing 10
     Alopecia 7
     Pulmonary
     Upper Respiratory    
     Tract Infection 10 7
     Pharyngitis 9210 
     Cardiovascular   
     Peripheral Edema 1011 
     Hepatic/Metabolic/Laboratory/Renal   
     Hematuria 6
     Dysuria
     * Event coded in WHO-ART dictionary 
     † No complete alopecia was reported.

    Clinically relevant adverse reactions in greater than or equal to 2% and less than 5% of the patients in the Oxaliplatin for Injection and fluorouracil/leucovorin combination arm (listed in decreasing order of frequency) were: anxiety, myalgia, erythematous rash, increased sweating, conjunctivitis, weight decrease, dry mouth, rectal hemorrhage, depression, ataxia, ascites, hemorrhoids, muscle weakness, nervousness, tachycardia, abnormal micturition frequency, dry skin, pruritus, hemoptysis, purpura, vaginal hemorrhage, melena, somnolence, pneumonia, proctitis, involuntary muscle contractions, intestinal obstruction, gingivitis, tenesmus, hot flashes, enlarged abdomen, and urinary incontinence.

    Table 13: Laboratory-Related Adverse Reactions Occurring in ≥5% of Patients with Previously Treated Advanced Colorectal Cancer
     Laboratory- Oxaliplatin and   
     Related Adverse FU/LV Oxaliplatin FU/LV
     Reaction N=150  N=153 N=142
        All Grades All Grades All Grades
      Grades 3 to 4 Grades 3 to 4 Grades 3 to 4
      (%) (%) (%) (%) (%) (%)
     Hematology      
     Anemia 81 2 64 1 68 2
     Leukopenia 76 19 13 0 34 1
     Neutropenia 73 44 7 0 25 5
     Thrombocytopenia 64 4 30 3 20 0
     Hepatic  
     Increased ALT*  31 0 36 1 28 3
     Increased AST 47 0 54 4 39 2
     Increased       
     Bilirubin  13 1 13 522 
     * Alanine transaminase
      Aspartate transaminase

    Additional Adverse Reactions

    The following adverse reactions were observed across clinical trials.

    Intravenous Site Reactions

    Injection site reaction, including redness, swelling, and pain, can occur with Oxaliplatin for Injection. In some cases, skin necrosis has occurred with extravasation.

    PRES

    PRES occurred in less than 0.1% of patients.

    Pulmonary Fibrosis and Interstitial Lung Disease

    Pulmonary fibrosis, which may be fatal, occurred in less than 1% of patients.

    6.2 Postmarketing Experience 

    The following adverse reactions have been identified during postapproval use of Oxaliplatin for Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    • General: angioedema, anaphylactic shock
    • Cardiovascular: QT prolongation leading to ventricular arrhythmias, including fatal torsade de pointes; bradyarrhythmia
    • Neurological: loss of deep tendon reflexes, dysarthria, Lhermitte’s sign, cranial nerve palsies, fasciculations, convulsion
    • Hearing and vestibular system: deafness
    • Infections: septic shock, including fatal outcomes
    • Infusion-related reactions and hypersensitivity reactions: laryngospasm
    • Hepatic and gastrointestinal: severe diarrhea/vomiting resulting in hypokalemia, colitis (including Clostridium difficile diarrhea), metabolic acidosis, ileus, intestinal obstruction, pancreatitis, sinusoidal obstruction syndrome, perisinusoidal fibrosis which rarely may progress, esophagitis
    • Musculoskeletal and connective tissue: rhabdomyolysis, including fatal outcomes
    • Platelet, bleeding, and clotting disorders: immuno-allergic thrombocytopenia, prolonged prothrombin time and INR in patients receiving anticoagulants
    • Blood disorders: secondary leukemia
    • Red blood cell: hemolytic uremic syndrome, immuno-allergic hemolytic anemia
    • Renal: acute tubular necrosis, acute interstitial nephritis, acute renal failure
    • Respiratory: interstitial lung diseases (sometimes fatal) and pneumonia (including fatal outcomes)
    • Vision: decrease of visual acuity, visual field disturbance, optic neuritis and transient vision loss (reversible following treatment discontinuation)
    • Injury, poisoning, and procedural complications: fall-related injuries
  • 7  DRUG INTERACTIONS

    7.1 Drugs that Prolong the QT Interval

    QT interval prolongation and ventricular arrhythmias can occur with Oxaliplatin for Injection [see Warnings and Precautions (5.7)]. Avoid coadministration of Oxaliplatin for Injection with medicinal products with a known potential to prolong the QT interval.

    7.2 Use with Nephrotoxic Products

    Because platinum-containing species are eliminated primarily through the kidney, clearance of these products may be decreased by coadministration of potentially nephrotoxic compounds [see Clinical Pharmacology (12.3)]. Avoid coadministration of Oxaliplatin for Injection with medicinal products known to cause nephrotoxicity.

    7.3 Use with Anticoagulants

    Prolonged prothrombin time and INR occasionally associated with hemorrhage have been reported in patients who received Oxaliplatin for Injection with fluorouracil/leucovorin while on anticoagulants [see Warnings and Precautions (5.10), Adverse Reactions (6.2)]. Increase frequency of monitoring in patients who are receiving Oxaliplatin for Injection with fluorouracil/leucovorin and oral anticoagulants.

  • 8  USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Based on its direct interaction with DNA, Oxaliplatin for Injection can cause fetal harm when administered to a pregnant woman. The available human data do not establish the presence or absence of major birth defects or miscarriage related to the use of Oxaliplatin for Injection. Reproductive toxicity studies demonstrated adverse effects on embryo-fetal development in rats at maternal doses that were below the recommended human dose based on body surface area (see Data). Advise a pregnant woman of the potential risk to a fetus.

    In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

    Data

    Animal data

    Pregnant rats were administered oxaliplatin at less than one-tenth the recommended human dose based on body surface area during gestation days (GD) 1 to 5 (preimplantation), GD 6 to 10, or GD 11 to 16 (during organogenesis). Oxaliplatin caused developmental mortality (increased early resorptions) when administered on days GD 6 to 10 and GD 11 to 16 and adversely affected fetal growth (decreased fetal weight, delayed ossification) when administered on days GD 6 to 10.

    8.2 Lactation

    Risk Summary

    There are no data on the presence of oxaliplatin or its metabolites in human or animal milk or its effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with Oxaliplatin for Injection and for 3 months after the final dose.

    8.3 Females and Males of Reproductive Potential 

    Pregnancy Testing

    Verify pregnancy status in females of reproductive potential prior to initiating Oxaliplatin for Injection [see Use in Specific Populations (8.1)].

    Contraception

    Oxaliplatin for Injection can cause embryo-fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].

    Females

    Advise female patients of reproductive potential to use effective contraception while receiving Oxaliplatin for Injection and for 9 months after the final dose.

    Males

    Based on its mechanism action as a genotoxic drug, advise males with female partners of reproductive potential to use effective contraception while receiving Oxaliplatin for Injection and for 6 months after the final dose [see Nonclinical Toxicology (13.1)].

    Infertility

    Based on animal studies, Oxaliplatin for Injection may impair fertility in males and females [see Nonclinical Toxicology (13.1)].

    8.4 Pediatric Use

    The safety and effectiveness of Oxaliplatin for Injection in pediatrics have not been established. Safety and effectiveness were assessed across 4 open-label studies in 235 patients aged 7 months to 22 years with solid tumors.

    In a multicenter, open-label, non-comparative, non-randomized study (ARD5531), oxaliplatin was administered to 43 patients with refractory or relapsed malignant solid tumors, mainly neuroblastoma and osteosarcoma. The dose limiting toxicity (DLT) was sensory neuropathy at a dose of 110 mg/m2. The main adverse reactions were: paresthesia (60%, grade 3 to 4: 7%), fever (40%, grade 3 to 4: 7%), and thrombocytopenia (40%, grade 3 to 4: 27%). No responses were observed.

    In an open-label non-randomized study (DFI7434), oxaliplatin was administered to 26 pediatric patients with metastatic or unresectable solid tumors, mainly neuroblastoma and ganglioneuroblastoma. The DLT was sensory neuropathy at a dose of 160 mg/m2. No responses were observed.

    In an open-label, single-agent study (ARD5021), oxaliplatin was administered to 43 pediatric patients with recurrent or refractory embryonal CNS tumors. The most common adverse reactions reported were: leukopenia (67%, grade 3 to 4: 12%), anemia (65%, grade 3 to 4: 5%), thrombocytopenia (65%, grade 3 to 4: 26%), vomiting (65%, grade 3 to 4: 7%), neutropenia (58%, grade 3 to 4: 16%), and sensory neuropathy (40%, grade 3 to 4: 5%).

    In an open-label single-agent study (ARD5530), oxaliplatin was administered to 123 pediatric patients with recurrent solid tumors, including neuroblastoma, osteosarcoma, Ewing sarcoma or peripheral PNET, ependymoma, rhabdomyosarcoma, hepatoblastoma, high grade astrocytoma, Brain stem glioma, low grade astrocytoma, malignant germ cell tumor and other tumors. The most common adverse reactions reported were: sensory neuropathy (52%, grade 3 to 4: 12%), thrombocytopenia (37%, grade 3 to 4: 17%), anemia (37%, grade 3 to 4: 9%), vomiting (26%, grade 3 to 4: 4%), increased ALT (24%, grade 3 to 4: 6%), increased AST (24%, grade 3 to 4: 2%), and nausea (23%, grade 3 to 4: 3%).

    The pharmacokinetic parameters of ultrafilterable platinum were evaluated in 105 pediatric patients during the first cycle. The mean clearance in pediatric patients estimated by the population pharmacokinetic analysis was 4.7 L/h (%CV, 41%). Mean platinum pharmacokinetic parameters in ultrafiltrate were Cmax of 0.75 ± 0.24 mcg/mL, AUC0-48h of 7.52 ± 5.07 mcg•h/mL and AUCinf of 8.83 ± 1.57 mcg•h/mL at 85 mg/m2 of oxaliplatin and Cmax of 1.10 ± 0.43 mcg/mL, AUC0-48h of 9.74 ± 2.52 mcg•h/mL and AUCinf of 17.3 ± 5.34 mcg•h/mL at 130 mg/m2 of oxaliplatin.

    8.5 Geriatric Use

    In the adjuvant treatment trial [see Clinical Studies (14.1)], 400 patients who received Oxaliplatin for Injection with fluorouracil/leucovorin were greater than or equal to 65 years. The effect of Oxaliplatin for Injection in patients greater than or equal to 65 years was not conclusive. Patients greater than or equal to 65 years receiving Oxaliplatin for Injection experienced more diarrhea and grade 3 to 4 neutropenia (45% vs 39%) compared to patients less than 65 years.  

    In the previously untreated advanced colorectal cancer trial [see Clinical Studies (14.2)], 99 patients who received Oxaliplatin for Injection with fluorouracil and leucovorin were greater than or equal to 65 years. The same efficacy improvements in response rate, time to tumor progression, and overall survival were observed in the greater than or equal to 65 years patients as in the overall study population. Adverse reactions were similar in patients less than 65 and greater than or equal to 65 years, but older patients may have been more susceptible to diarrhea, dehydration, hypokalemia, leukopenia, fatigue, and syncope.

    In the previously treated advanced colorectal cancer trial [see Clinical Studies (14.3)], 55 patients who received Oxaliplatin for Injection with fluorouracil and leucovorin were greater than or equal to 65 years. No overall differences in effectiveness were observed between these patients and younger adults. Adverse reactions were similar in patients less than 65 and greater than or equal to 65 years, but older patients may have been more susceptible to diarrhea, dehydration, hypokalemia, and fatigue.

    No significant effect of age on the clearance of ultrafilterable platinum has been observed [see Clinical Pharmacology (12.3)].

    8.6 Patients with Renal Impairment 

    The AUC of unbound platinum in plasma ultrafiltrate was increased in patients with renal impairment [see Clinical Pharmacology (12.3)]. No dose reduction is recommended for patients with mild (creatinine clearance 50 to 79 mL/min) or moderate (creatinine clearance 30 to 49 mL/min) renal impairment, calculated by Cockcroft-Gault equation. Reduce the dose of Oxaliplatin for Injection in patients with severe renal impairment (creatinine clearance less than 30 mL/min) [see Dosage and Administration (2.3)].

  • 10  OVERDOSAGE

    The maximum dose of oxaliplatin that has been administered in a single infusion is 825 mg. Several cases of overdoses have been reported with Oxaliplatin for Injection. Adverse reactions observed following an overdosage were grade 4 thrombocytopenia (less than 25,000/mm3) without bleeding, anemia, sensory neuropathy (including paresthesia, dysesthesia, laryngospasm and facial muscle spasms), gastrointestinal disorders (including nausea, vomiting, stomatitis, flatulence, abdomen enlarged and grade 4 intestinal obstruction), grade 4 dehydration, dyspnea, wheezing, chest pain, respiratory failure, severe bradycardia and death.

    Closely monitor patients suspected of receiving an overdose, including for the adverse reactions described above and administer appropriate supportive treatment.

  • 11  DESCRIPTION

    Oxaliplatin for Injection, USP is a platinum-based drug with the molecular formula C8H14N2O4Pt and the chemical name of cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N’] [oxalato(2-)-O,O’] platinum. Oxaliplatin, USP is an organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a leaving group.

    structural formula

    The molecular weight is 397.29. Oxaliplatin, USP is slightly soluble in water at 6 mg/mL, very slightly soluble in methanol, and practically insoluble in ethanol and acetone.

    Powder for solution for infusion:

    Oxaliplatin for Injection USP, for intravenous use is supplied in vials containing 50 mg or 100 mg of oxaliplatin, USP as a sterile, preservative-free lyophilized powder for reconstitution. Lactose monohydrate is present as an inactive ingredient at 450 mg and 900 mg in the 50 mg and 100 mg dosage strengths, respectively.

  • 12  CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter-and intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.

    In vivo studies have shown antitumor activity of oxaliplatin against colon carcinoma. In combination with fluorouracil, oxaliplatin exhibits in vitro and in vivo antiproliferative activity greater than either compound alone in several tumor models (HT29 [colon], GR [mammary], and L1210 [leukemia]).

    12.2 Pharmacodynamics

    A pharmacodynamic relationship between platinum ultrafiltrate levels and clinical safety and effectiveness has not been established.

    12.3 Pharmacokinetics 

    The reactive oxaliplatin derivatives are present as a fraction of the unbound platinum in plasma ultrafiltrate. After a single 2-hour intravenous infusion of Oxaliplatin for Injection at a dose of 85 mg/m2, pharmacokinetic parameters expressed as ultrafilterable platinum were Cmax of 0.814 mcg/mL and volume of distribution of 440 L.

    Interpatient and intrapatient variability in ultrafilterable platinum exposure (AUC0-48hr) assessed over 3 cycles was 23% and 6%, respectively.

    Distribution

    At the end of a 2-hour infusion of Oxaliplatin for Injection, approximately 15% of the administered platinum is present in the systemic circulation. The remaining 85% is rapidly distributed into tissues or eliminated in the urine. The decline of ultrafilterable platinum levels following Oxaliplatin for Injection administration is triphasic, including two distribution phases (t1/2α; 0.43 hours and t1/2β; 16.8 hours).

    In patients, plasma protein binding of platinum is irreversible and is greater than 90%. The main binding proteins are albumin and gamma-globulins.

    Platinum also binds irreversibly and accumulates (approximately 2-fold) in erythrocytes, where it appears to have no relevant activity. No platinum accumulation was observed in plasma ultrafiltrate following 85 mg/m2 every two weeks.

    Elimination

    The decline of ultrafilterable platinum concentrations from plasma is characterized by a long terminal elimination phase (t1/2γ; 392 hours).

    Metabolism

    Oxaliplatin undergoes rapid and extensive nonenzymatic biotransformation. There is no evidence of cytochrome P450-mediated metabolism in vitro.

    Up to 17 platinum-containing derivatives have been observed in plasma ultrafiltrate samples from patients, including several cytotoxic species (monochloro DACH platinum, dichloro DACH platinum, and monoaquo and diaquo DACH platinum) and a number of noncytotoxic, conjugated species.

    Excretion

    The major route of platinum elimination is renal excretion. At five days after a single 2-hour infusion of Oxaliplatin for Injection, urinary elimination accounted for about 54% of the platinum eliminated, with fecal excretion accounting for only about 2%. Platinum was cleared from plasma at a rate (10 to 17 L/h) that was similar to or exceeded the average human glomerular filtration rate (GFR; 7.5 L/h). The renal clearance of ultrafilterable platinum is significantly correlated with GFR.

    Special Populations

    Sex

    There was no significant effect of sex on the clearance of ultrafilterable platinum.

    Patients with Renal Impairment

    Patients with normal function (CLcr greater than 80 mL/min) and patients with mild (CLcr=50 to 80 mL/min) and moderate (CLcr equal to 30 to 49 mL/min) renal impairment received Oxaliplatin for Injection 85 mg/m2 and those with severe (CLcr less than 30 mL/min) renal impairment received Oxaliplatin for Injection 65 mg/m2. Mean dose adjusted AUC of unbound platinum was 40%, 95%, and 342% higher for patients with mild, moderate, and severe renal impairment, respectively, compared to patients with normal renal function. Mean dose adjusted Cmax of unbound platinum appeared to be similar among the normal, mild and moderate renal function groups, but was 38% higher in the severe group than in the normal group [see Dosage and Administration (2.3)].

    Drug Interaction Studies

    No pharmacokinetic interaction between Oxaliplatin for Injection 85 mg/m2 and infusional fluorouracil has been observed in patients treated every 2 weeks, but increases of fluorouracil plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 of Oxaliplatin for Injection administered every 3 weeks.

    In vitro platinum was not displaced from plasma proteins by the following medications: erythromycin, salicylate, sodium valproate, granisetron, and paclitaxel.

    In vitro oxaliplatin does not inhibit human cytochrome P450 isoenzymes.

  • 13  NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 

    Long-term animal studies have not been performed to evaluate the carcinogenic potential of oxaliplatin. Oxaliplatin was not mutagenic to bacteria (Ames test) but was mutagenic to mammalian cells in vitro (L5178Y mouse lymphoma assay). Oxaliplatin was clastogenic both in vitro (chromosome aberration in human lymphocytes) and in vivo (mouse bone marrow micronucleus assay).

    In a fertility study, male rats were given oxaliplatin at 0, 0.5, 1, or 2 mg/kg/day for five days every 21 days for a total of three cycles prior to mating with females that received two cycles of oxaliplatin on the same schedule. A dose of 2 mg/kg/day (less than one-seventh the recommended human dose on a body surface area basis) did not affect pregnancy rate, but resulted in 97% postimplantation loss (increased early resorptions, decreased live fetuses, decreased live births) and delayed growth (decreased fetal weight).

    Testicular damage, characterized by degeneration, hypoplasia, and atrophy, was observed in dogs administered oxaliplatin at 0.75 mg/kg/day (approximately one-sixth of the recommended human dose on a body surface area basis) × 5 days every 28 days for three cycles. A no effect level was not identified.

  • 14  CLINICAL STUDIES

    14.1 Adjuvant Treatment with Oxaliplatin for Injection in Combination with Fluorouracil and Leucovorin

    The efficacy of Oxaliplatin for Injection in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in an international, multicenter, randomized (1:1) trial (The Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer [MOSAIC], NCT00275210) in patients with stage II (Dukes’ B2) or III (Dukes’ C) colon cancer who had undergone complete resection of the primary tumor. Patients were randomized to receive Oxaliplatin for Injection with fluorouracil/leucovorin or fluorouracil/leucovorin alone for a total of 6 months (i.e., 12 cycles). Table 14 shows the dosing regimens for the two arms.

    Eligible patients were between 18 and 75 years of age, had histologically proven stage II (T3-T4 N0 M0; Dukes’ B2) or III (any T N1-2 M0; Dukes’ C) colon carcinoma (with the inferior pole of the tumor above the peritoneal reflection, i.e., greater than or equal to 15 cm from the anal margin) and had undergone (within 7 weeks prior to randomization) complete resection of the primary tumor without gross or microscopic evidence of residual disease and carcino-embyrogenic antigen (CEA) less than 10 ng/mL. Additional eligibility criteria were no prior chemotherapy, immunotherapy or radiotherapy; Eastern Cooperative Oncology Group performance status of 0, 1, or 2 (Karnofsky Performance Status greater than or equal to 60%); no pre-existing neuropathy; and absolute neutrophil count (ANC) greater than or equal to 1.5 × 109/L, platelets greater than or equal to 100 × 109/L, serum creatinine less than or equal to 1.25 × upper limit normal (ULN), total bilirubin less than 2 × ULN, and aspartate transaminase (AST)/alanine transaminase (ALT) less than 2 × ULN. The major efficacy outcome was 3-year disease-free survival (DFS).

    Table 14: Dosing Regimens in Adjuvant Treatment Study
     Treatment  
     Arm Dose Regimen
     Oxaliplatin + Day 1: Oxaliplatin for Injection: 85 mg/m2 (2-hour infusion) + LV: 200 mg/m2 (2-hour infusion), followed by  every 2 weeks
     FU/LV FU: 400 mg/m2 (bolus), 600 mg/m2 (22-hour infusion) 12 cycles
     (FOLFOX4)  
     (N =1123)  
      Day 2: LV: 200 mg/m2 (2-hour infusion), followed by FU:  
      400 mg/m2 (bolus), 600 mg/m2 (22-hour infusion)  
     FU/LV Day 1: LV: 200 mg/m2 (2-hour infusion), followed by FU:  every 2 weeks
     (N=1123) 400 mg/m2 (bolus), 600 mg/m2 (22-hour infusion) 12 cycles
      Day 2: LV: 200 mg/m2 (2-hour infusion),  
      followed by FU: 400 mg/m2 (bolus), 600 mg/m2 (22-hour infusion) 
       

    There were 2246 patients enrolled, of whom 1347 (60%) had Stage III disease. Tables 15 and 16 show the baseline characteristics and exposure to Oxaliplatin for Injection.

    Table 15: Baseline Characteristics in Adjuvant Treatment Study
      Oxaliplatin + Infusional  
      FU/LV Infusional FU/LV
      N=1123 N=1123
     Sex: Male (%) 56.1 52.4
     Female (%) 43.9 47.6
     Median age (years) 61.0 60.0
     <65 years of age (%) 64.4 66.2
     ≥65 years of age (%) 35.6 33.8
     KPS (%)
     100 29.7 30.5
     90 52.2 53.9
     80 4.4 3.3
     70 13.2 11.9
     ≤60 0.6 0.4
     Primary site (%)
     Colon including cecum 54.6 54.4
     Sigmoid 31.9 33.8
     Recto sigmoid 12.9 10.9
     Other including rectum 0.6 0.9
     Bowel obstruction (%)
     Yes 17.9 19.3
     Perforation (%)
     Yes 6.9 6.9
     Stage at Randomization (%)
     II (T=3,4 N=0, M=0) 40.1 39.9
     III (T=any, N=1,2, M=0) 59.6 59.3
     IV (T=any, N=any, M=1) 0.4 0.8
     Staging - T (%)
     T1 0.5 0.7
     T2 4.5 4.8
     T3 76.0 75.9
     T4 19.0 18.5
     Staging - N (%)
     N0 40.2 39.9
     N1 39.4 39.4
     N2 20.4 20.7
     Staging - M (%)
     M1 0.4 0.8
    Table 16: Exposure to Oxaliplatin for Injection in Adjuvant Treatment Study
      Oxaliplatin + Infusional
      Infusional FU/LV FU/LV
      N=1108 N=1111
     Median Relative Dose Intensity (%)
        FU 84.4 97.7
        Oxaliplatin for Injection 80.5 N/A
     Median Number of Cycles 12 12
     Median Number of Cycles with Oxaliplatin for Injection 11 N/A

    The median duration of follow-up was approximately 77 months. In the overall and the stage III colon cancer populations, DFS was statistically significantly improved in the Oxaliplatin for Injection-containing arm compared to fluorouracil/leucovorin alone; however, a statistically significant improvement in DFS was not observed in Stage II patients. No significant differences in overall survival (OS) were detected in the overall population or those with Stage III disease. Table 17 and Figures 1 and 2 summarize the 5-year DFS rates in the overall randomized population and in patients with stage II and III disease based on an intention-to-treat (ITT) analysis.

    Table 17: Summary of DFS Analysis in Adjuvant Treatment Study - ITT Population
      Oxaliplatin + 
      Infusional FU/LV Infusional FU/LV
     A hazard ratio of less than 1 favors Oxaliplatin  + Infusional FU/LV
     Data cut off for disease-free survival June 1, 2006
     Parameter  
     Overall
     Number of patients 1123 1123
     Number of events - relapse or death (%) 304 (27.1) 360 (32.1)
      5-yr Disease-free survival % (95% CI) 73.3 (70.7, 76.0) 67.4 (64.6, 70.2)
     Hazard ratio (95% CI) 0.80 (0.68, 0.93)
     Stratified Log rank test p=0.003
     Stage III (Dukes' C)
    Number of patients 672 675
     Number of events - relapse or death (%) 226 (33.6) 271 (40.1)
     5-yr Disease-free survival % (95% CI) 66.4 (62.7, 70.0) 58.9 (55.2, 62.7)
     Hazard ratio (95% CI) 0.78 (0.65, 0.93)

       Log rank test

     p=0.005
     Stage II (Dukes' B2)
     Number of patients 451 448
     Number of events - relapse or death (%) 78 (17.3) 89 (19.9)
     5-yr Disease-free survival % (95% CI) 83.7 (80.2, 87.1) 79.9 (76.2, 83.7)
     Hazard ratio (95% CI) 0.84 (0.62, 1.14)

    Log rank test

     p=0.258
    bc49511e-figure-03

    Figure 1: Kaplan-Meier Curves of Disease-Free Survival (cutoff: 1 June 2006) in Adjuvant Treatment Trial – ITT Population

    bc49511e-figure-04

    Figure 2: Kaplan-Meier Curves of Disease-Free Survival in Stage III Patients (cutoff: 1 June 2006) in Adjuvant Treatment Trial – ITT Population

    Table 18 summarizes the OS results in the overall randomized population and in patients with stage II and III disease, based on the ITT analysis.

    Table 18: Summary of OS Analysis in Adjuvant Treatment - ITT Population
     Parameter Oxaliplatin + Infusional FU/LV
      Infusional FU/LV 
     A hazard ratio of less than 1 favors Oxaliplatin + Infusional FU/LV 
     Data cut off for overall survival January 16, 2007
     Overall
     Number of patients 1123 1123
     Number of death events (%) 245 (21.8) 283 (25.2)
     Hazard ratio (95% CI) 0.84 (0.71, 1.00)
     Stage III (Dukes' C)
     Number of patients 672 675
     Number of death events (%) 182 (27.1) 220 (32.6)
     Hazard ratio (95% CI) 0.80 (0.65, 0.97)
     Stage II (Dukes' B2)
     Number of patients 451 448
     Number of death events (%) 63 (14.0) 63 (14.1)
     Hazard ratio (95% CI) 1.00 (0.70, 1.41)

    14.2 Previously Untreated Advanced Colorectal Cancer 

    The efficacy of Oxaliplatin for Injection in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in a North American, multicenter, open-label, randomized, active-controlled trial (A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients with Advanced Adenocarcinoma of the Colon and Rectum; NCT00003594). The trial included 7 arms at different times during its conduct, four of which were closed due to either changes in the standard of care, toxicity, or simplification. During the trial, the control arm was changed to irinotecan with fluorouracil/leucovorin.

    The results reported below compared the efficacy of Oxaliplatin for Injection with fluorouracil/leucovorin and Oxaliplatin for Injection with irinotecan to an approved control regimen of irinotecan with fluorouracil/leucovorin in 795 concurrently randomized patients previously untreated for locally advanced or metastatic colorectal cancer. Table 19 presents the dosing regimens for the three arms. After completion of enrollment, the dose of irinotecan with fluorouracil/leucovorin was decreased due to toxicity.

    Eligible patients were at least 18 years of age; had known locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma not curable by surgery or amenable to radiation therapy; with an Eastern Cooperative Oncology Group (ECOG) performance status ≤0, 1, or 2. Patients had to have absolute neutrophil count (ANC) greater than or equal to 1.5 × 109/L, platelets greater than or equal to 100 × 109/L, hemoglobin greater than or equal to 9.0 g/dL, creatinine less than or equal to 1.5 × upper limit of normal (ULN), total bilirubin less than or equal to 1.5 mg/dL, aspartate transaminase (AST)  less than or equal to 5 × ULN, and alkaline phosphatase less than or equal to 5 × ULN. Patients may have received adjuvant treatment for resected Stage II or III disease without recurrence within 12 months. Randomization was stratified by ECOG performance status (0, 1 vs 2), prior adjuvant chemotherapy (yes vs no), prior immunotherapy (yes vs no), and age (less than 65 vs greater than or equal to 65 years). Although no post study treatment was specified in the protocol, 65% to 72% of patients received additional post study chemotherapy after study treatment discontinuation on all arms. Fifty-eight percent of patients on the Oxaliplatin for Injection with fluorouracil/leucovorin arm received an irinotecan-containing regimen and 23% of patients on the irinotecan with fluorouracil/leucovorin arm received an oxaliplatin-containing regimen. The main efficacy outcome measure was 3-year disease-free survival (DFS) and additional efficacy outcome measures were overall survival (OS). 

    Table 19: Dosing Regimens for Previously Untreated Advanced Colorectal Cancer Clinical Trial 
     Treatment Arm Dose Regimen
     Oxaliplatin + FU/LV Day 1: Oxaliplatin for Injection: 85 mg/m2 (2-hour infusion) + LV 200 mg/m2 every 2
     (FOLFOX4) (2-hour infusion), followed by FU: 400 mg/m2 (bolus), 600 mg/m2 (22-hour  weeks
      (N=267) infusion) 
       
      Day 2: LV 200 mg/m2 (2-hour infusion), followed by FU: 400 mg/m2 
       (bolus), 600 mg/m2 (22-hour infusion) 
       
     Irinotecan + Day 1: irinotecan 125 mg/m2 as a 90–min infusion + LV 20 mg/m2 every 6
     FU/LV as a 15-min infusion or intravenous push, followed by weeks
     (IFL) FU 500 mg/m2 intravenous bolus weekly x 4 
     (N=264)  
       
     Oxaliplatin + Day 1: Oxaliplatin for Injection: 85 mg/m2 intravenous (2-hour infusion) + every 3
     Irinotecan irinotecan 200 mg/m2 intravenous over 30 minutes weeks
     (IROX)  
      (N=264)  

    Table 20 presents the baseline characteristics.

    Table 20: Baseline Characteristics for Previously Untreated Advanced Colorectal Cancer Clinical Trial
      Oxaliplatin +  Irinotecan + Oxaliplatin +
      FU/LV FU/LV Irinotecan
      N=267 N=264 N=264
     Sex: Male (%)  58.8 65.2 61.0
          Female (%)  41.2 34.8 39.0
     Median age (years)  61.0 61.0 61.0
     <65 years of age (%)  61 62 63
     ≥65 years of age (%)  39 38 37
     ECOG (%)    
     0 to 1  94.4 95.5 94.7
     2  5.6 4.5 5.3
     Involved organs (%)    
       Colon only  0.7 0.8 0.4
       Liver only  39.3 44.3 39.0
       Liver + other  41.2 38.6 40.9
       Lung only  6.4 3.8 5.3
       Other (including lymph nodes)  11.6 11.0 12.9
       Not reported  0.7 1.5 1.5
     Prior radiation (%)  3.0 1.5 3.0
     Prior surgery (%)  74.5 79.2 81.8
     Prior adjuvant (%)  15.7 14.8 15.2

    The median number of cycles administered per patient was 10 (23.9 weeks) for the Oxaliplatin for Injection plus fluorouracil/leucovorin regimen, 4 (23.6 weeks) for the irinotecan plus fluorouracil/leucovorin regimen, and 7 (21.0 weeks) for the Oxaliplatin for Injection plus irinotecan regimen.

    Patients who received Oxaliplatin for Injection with fluorouracil/leucovorin had a significantly longer time to tumor progression based on investigator assessment, longer OS, and a significantly higher confirmed response rate based on investigator assessment compared to patients who received irinotecan with fluorouracil/leucovorin. Efficacy results are summarized in Table 21 and Figure 3.

    Table 21: Efficacy Results for Previously Untreated Advanced Colorectal Cancer Trial
      Oxaliplatin + Irinotecan + Oxaliplatin +
      FU/LV  FU/LV Irinotecan
      N=267 N=264 N=264
     * Compared to irinotecan plus fluorouracil/leucovorin (IFL) arm.
     A hazard ratio of less than 1 favors Oxaliplatin + Infusional FU/LV. 
     ‡ Based on all patients with measurable disease at baseline.
     The numbers in the response rate and TTP analysis are based on unblinded investigator assessment.
     Survival (ITT)    
     Number of deaths (%)  155 (58.1) 192 (72.7) 175 (66.3)
     Median survival (months)  19.4 14.6 17.6
     Hazard ratio (95% CI) 0.65 (0.53, 0.80)  - 
     P-value  <0.0001*  -
     TTP (ITT, investigator assessment)    
     Percentage of progressors  82.8 81.8 89.4
     Median TTP (months)  8.7 6.9 6.5
     Hazard ratio (95% CI) 0.74 (0.61, 0.89)  -
     P-value  0.0014*  -
     Response Rate (investigator assessment)   
     Patients with measurable disease  210 212 215
     Complete response, N (%)  13 (6.2) 5 (2.4) 7 (3.3)
     Partial response, N (%)  82 (39.0) 64 (30.2) 67 (31.2)
     Complete and partial response, N (%)  95 (45.2) 69 (32.5) 74 (34.4)
     95% CI  (38.5, 52.0) (26.2, 38.9) (28.1, 40.8)
     P-value  0.0080*  -
    bc49511e-figure-05

    Figure 3: Kaplan-Meier Curves for Overall Survival in Previously Untreated Advanced Colorectal Cancer Trial

    In descriptive subgroup analyses, the improvement in overall survival (OS) for Oxaliplatin for Injection with fluorouracil/leucovorin compared to irinotecan with fluorouracil/leucovorin appeared to be maintained across age groups, prior adjuvant treatment, number of organs involved  and both sexes; however, the effect appeared larger among women than men.

    14.3 Previously Treated Advanced Colorectal Cancer  

    The efficacy of Oxaliplatin for Injection in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in a multicenter, open-label, randomized, three-arm controlled trial was conducted in the US and Canada in patients with advanced colorectal cancer who had relapsed/progressed during or within 6 months of first-line treatment with bolus fluorouracil/leucovorin and irinotecan (A multicenter, open-label, randomized, three-arm study of 5-fluorouracil (5-FU) + leucovorin (LV) or oxaliplatin or a combination of 5-FU/LV + oxaliplatin as second-line treatment of metastatic colorectal carcinoma: NCT00008281). Patients were randomized to one of three regimens; the dosing regimens are presented in Table 22. Eligible patients were at least 18 years of age, had unresectable, measurable, histologically proven colorectal adenocarcinoma, with a Karnofsky performance status (KPS) greater than 50%. Patients had to have aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase less than or equal to 2 × upper limit of normal (ULN), unless liver metastases were present and documented at baseline by CT or MRI scan, in which case less than or equal to 5 × ULN was permitted. Prior radiotherapy was permitted if it had been completed at least 3 weeks before randomization. The main efficacy outcome measure was 3-year disease-free survival (DFS) and an additional outcome measure was overall survival (OS).

    Table 22: Dosing Regimens in Refractory and Relapsed Colorectal Cancer Trial
      Treatment   
      Arm  Dose  Regimen
     Oxaliplatin + Day 1: Oxaliplatin for Injection: 85 mg/m2 (2-hour infusion) + LV 200 mg/m2 (2-hour  every 2
     FU/LV infusion), followed by FU: 400mg/m2 (bolus), 600 mg/m2 (22-hour infusion) weeks
     (N =152)  
       
      Day 2: LV 200 mg/m2 (2-hour infusion), followed by FU: 400 mg/m2 (bolus), 600 mg/m2 (22-hour 
      infusion) 
       
     FU/LV Day 1: LV 200 mg/m2 (2-hour infusion), followed by FU: 400 mg/m2 (bolus), 600 mg/m2 (22-hour every 2
     (N=151) infusion) weeks
       
       
      Day 2: LV 200 mg/m2 (2-hour infusion), followed by FU: 400 mg/m2 (bolus), 600 mg/m2 (22-hour 
      infusion) 
       
     Oxaliplatin Day 1: Oxaliplatin for Injection 85 mg/m2 (2-hour infusion)  every 2
     (N=156)  weeks

    Patients must have had at least one unidimensional lesion measuring greater than or equal to 20 mm using conventional CT or MRI scans or greater than or equal to 10 mm using a spiral CT scan. Tumor response and progression were assessed every 3 cycles (6 weeks) using the Response Evaluation Criteria in Solid Tumors (RECIST) until radiological documentation of progression or for 13 months following the first dose of study drug(s), whichever came first. Confirmed responses were based on two tumor assessments separated by at least 4 weeks. Baseline characteristics are shown in Table 23.

    Table 23: Baseline Characteristics in Refractory and Relapsed Colorectal Cancer Trial
      Oxaliplatin + Oxaliplatin FU/LV
     FU/LV  N=156N=151 
      N=152  
     Sex: Male (%) 57.2 60.9 54.3
          Female (%) 42.8 39.1 45.7
     Median age (years) 59.0 61.0 60.0
          Range 22 to 88 27 to 79 21 to 80
     Race (%)
          Caucasian 88.8 84.6 87.4
          Black 5.9 7.1 7.9
          Asian 2.6 2.6 1.3
          Other 2.6 5.8 3.3
     KPS (%)
          70 to 100 95.4 92.3 94.7
          50 to 60 2.0 4.5 2.6
          Not reported 2.6 3.2 2.6
     Prior radiotherapy (%) 25.0 19.2 25.2
     Prior pelvic radiation (%) 21.1 13.5 18.5
     Number of metastatic sites (%)
          1 25.7 31.4 27.2
          ≥2 74.3 67.9 72.2
     Liver involvement (%)
          Liver only 18.4 25.6 22.5
          Liver + other 53.3 59.0 60.3

    The median number of cycles administered per patient was 6 for the Oxaliplatin for Injection and fluorouracil/leucovorin combination and 3 each for fluorouracil/leucovorin alone and Oxaliplatin for Injection alone. Patients treated with the combination of Oxaliplatin for Injection and fluorouracil/leucovorin had an increased response rate compared to patients given fluorouracil/leucovorin or oxaliplatin alone. Efficacy results are summarized in Tables 24 and 25.

    Table 24: Response Rates in Refractory and Relapsed Colorectal Cancer Clinical Trial - ITT Analysis
     Oxaliplatin +  
     Best ResponseFU/LVOxaliplatin FU/LV
       N=152N=156  N=151
     Complete Response 0 0 0
     Partial Response 13 (9%) 2 (1%) 0
     P-value 0.0002 FU/LV vs Oxaliplatin + FU/LV
     95% CI 4.6%, 14.2% 0.2%, 4.6% 0, 2.4%
    Table 25: Radiographic Time to Progression (TTP)* in Refractory and Relapsed Colorectal Cancer Clinical Trial
     Oxaliplatin +    
      FU/LV Oxaliplatin FU/LV
     Arm  N=152 N=156 N=151
    * This is not an ITT analysis. Events were limited to radiographic disease progression documented by independent review of radiographs. Clinical progression was not included in this analysis, and 18% of patients were excluded from the analysis based on unavailability of the radiographs for independent review.
     Number of progressors 50 101 74
     Number of patients with no radiological  17 (11%) 16 (10%) 22 (15%)
     evaluation beyond baseline   
     Median TTP (months) 4.6 1.6 2.7
     95% CI 4.2, 6.1 1.4, 2.7 1.8, 3.0

    At the time of the interim analysis 49% of the radiographic progression events had occurred. In this interim analysis an estimated 2-month increase in median time to radiographic progression was observed compared to fluorouracil/leucovorin alone.

  • 15  REFERENCES

    1. “OSHA Hazardous Drugs.” OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html
  • 16  HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How Supplied

    Oxaliplatin for Injection, USP is supplied in clear, glass, single-dose vials with gray elastomeric stoppers and aluminum flip-off seals containing 50 mg or 100 mg of oxaliplatin, USP as a sterile, preservative-free, lyophilized powder for reconstitution. Lactose monohydrate is also present as an inactive ingredient.

    50 mg single-dose vial with green flip-off seal individually packaged in a carton NDC 45963-611-53.

    100 mg single-dose vial with green flip-off seal individually packaged in a carton NDC 45963-611-59.

    Lyophilized
    Sterile, Nonpyrogenic, Preservative-free
    The container closure is not made with natural rubber latex.

    16.2 Storage

    Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP controlled room temperature].

    Retain in carton until time of use. Discard unused portion.

    Oxaliplatin for Injection, USP is a cytotoxic drug. Follow applicable special handling and disposal procedures.1 The use of gloves is recommended. If a solution of Oxaliplatin for Injection, USP contacts the skin, wash the skin immediately and thoroughly with soap and water. If Oxaliplatin for Injection, USP contacts the mucous membranes, flush thoroughly with water.

  • 17  PATIENT COUNSELING INFORMATION

    Hypersensitivity Reactions

    Advise patients of the potential risk of hypersensitivity and that Oxaliplatin for Injection is contraindicated in patients with a history of hypersensitivity reactions to oxaliplatin and other platinum-based drugs. Instruct patients to seek immediate medical attention for signs of severe hypersensitivity reaction such as chest tightness; shortness of breath; wheezing; dizziness or faintness; or swelling of the face, eyelids, or lips [see Warnings and Precautions (5.1)].

    Peripheral Sensory Neuropathy

    Advise patients of the risk of acute reversible or persistent-type neurosensory toxicity. Advise patients to avoid cold drinks, use of ice, and exposure of skin to cold temperature or cold objects [see Warnings and Precautions (5.2)].

    Myelosuppression

    Inform patients that Oxaliplatin for Injection can cause low blood cell counts and the need for frequent monitoring of blood cell counts. Advise patients to contact their healthcare provider immediately for bleeding, fever, particularly if associated with persistent diarrhea, or symptoms of infection develop [see Warnings and Precautions (5.3)].

    Posterior Reversible Encephalopathy Syndrome

    Advise patients of the potential effects of vision abnormalities, in particular transient vision loss (reversible following therapy discontinuation), which may affect the patients' ability to drive and use machines [see Warnings and Precautions (5.4)].

    Pulmonary Toxicity

    Advise patients to report immediately to their healthcare provider any persistent or recurrent respiratory symptoms, such as non-productive cough and dyspnea [see Warnings and Precautions (5.5)].

    Hepatotoxicity

    Advise patients to report signs or symptoms of hepatic toxicity to their healthcare provider [see Warnings and Precautions (5.6)].

    QT Interval Prolongation

    Advise patients that Oxaliplatin for Injection can cause QTc interval prolongation and to inform their physician if they have any symptoms, such as syncope [see Warnings and Precautions (5.7)].

    Rhabdomyolysis

    Advise patients to contact their healthcare provider immediately for new or worsening signs or symptoms of muscle toxicity, dark urine, decreased urine output, or the inability to urinate [see Warnings and Precautions (5.8)].

    Hemorrhage

    Advise patients that Oxaliplatin for Injection may increase the risk of bleeding and to promptly inform their healthcare provider of any bleeding episodes [see Warnings and Precautions (5.9)].

    Embryo-Fetal Toxicity

    Advise females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.10), Use in Specific Populations (8.1)].

    Advise females of reproductive potential to use effective contraception during treatment with Oxaliplatin for Injection and for 9 months after the final dose [see Use in Specific Populations (8.3)].

    Advise male patients with female partners of reproductive potential to use effective contraception during treatment with Oxaliplatin for Injection and for 6 months after the final dose [see Use in Specific Populations (8.3), Nonclinical Toxicology (13.1)].

    Lactation

    Advise women not to breastfeed during treatment with Oxaliplatin for Injection and for 3 months after the final dose [see Use in Specific Populations (8.2)].

    Infertility

    Advise females and males of reproductive potential that Oxaliplatin for Injection may impair fertility [see Use in Specific Populations (8.3), Nonclinical Toxicology (13.1)].

    Gastrointestinal

    Advise patients to contact their healthcare provider for persistent vomiting, diarrhea, or signs of dehydration [see Adverse Reactions (6.1)].

    Drug Interactions

    Inform patients about the risk of drug interactions and the importance of providing a list of prescription and nonprescription drugs to their healthcare provider [see Drug Interactions (7)].

    Manufactured by:
    Sindan Pharma SRL
    11 Ion Mihalache Blvd
    Bucharest 1, Romania 011171

    Distributed by:
    Actavis Pharma, Inc.
    Parsippany, NJ 07054 USA

    Rev. B 10/2020

  • PATIENT INFORMATION

    Oxaliplatin (ox al" i pla' tin) for Injection, USP
    for intravenous use

     

    What is the most important information I should know about Oxaliplatin for Injection?

    Oxaliplatin for Injection can cause serious allergic reactions, including allergic reactions that can lead to death. Oxaliplatin for Injection is a platinum-based medicine. Serious allergic reactions including death can happen in people who take Oxaliplatin for Injection and who have had previous allergic reactions to platinum-based medicines. Serious allergic reactions can happen within a few minutes of your Oxaliplatin for Injection infusion or any time during your treatment with Oxaliplatin for Injection.

    Get emergency help right away if you:

    • have trouble breathing
    • feel like your throat is closing up

    Call your doctor right away if you have any of the following signs or symptoms of an allergic reaction:

    • rash
    • flushed face
    • hives
    • itching
    • swelling of your lips or tongue
    • sudden cough
    • dizziness or feel faint
    • sweating
    • chest pain

    See “What are the possible side effects of Oxaliplatin for Injection?” for information about other serious side effects.

    What is Oxaliplatin for Injection?

    Oxaliplatin for Injection is an anti-cancer (chemotherapy) medicine that is used with other anti-cancer medicines called fluorouracil and leucovorin to treat people with:

    • stage III colon cancer after surgery to remove the tumor
    • advanced colon or rectal cancer (colorectal cancer)

    It is not known if Oxaliplatin for Injection is effective in children.

    Who should not receive Oxaliplatin for Injection?

    Do not receive Oxaliplatin for Injection if you are allergic to any of the ingredients in Oxaliplatin for Injection or other medicines that contain platinum. See the end of this leaflet for a complete list of the ingredients Oxaliplatin for Injection.

    Ask your doctor if you are not sure if you take a medicine that contains platinum.

    What should I tell my doctor before receiving Oxaliplatin for Injection?

    Before receiving Oxaliplatin for Injection, tell your doctor about all of your medical conditions, including if you:

    • have an infection
    • have lung, liver, or kidney problems
    • have bleeding problems
    • have or had heart problems such as an abnormal heart test called an electrocardiogram (ECG or EKG), a condition called long QT syndrome, an irregular or slow heartbeat, or a family history of heart problems.
    • have had changes in the level of certain blood salt (electrolytes) levels, including potassium, magnesium, and calcium
    • are pregnant or plan to become pregnant. Oxaliplatin for Injection may harm your unborn baby. Tell your doctor right away if you become pregnant or think you may be pregnant during treatment with Oxaliplatin for Injection.
    • if you are able to become pregnant, your doctor may do a pregnancy test before you start treatment with Oxaliplatin for Injection and for 9 months after the final dose. Talk to your doctor about forms of birth control that may be right for you.
    • Females who are able to become pregnant should avoid becoming pregnant and should use effective birth control during treatment with Oxaliplatin for Injection and for 9 months after the final dose. Talk to your doctor about forms of birth control that may be right for you.
    • Males with female partners who are pregnant or able to become pregnant should use effective birth control during treatment with Oxaliplatin for Injection and for 6 months after the final dose.
    • Oxaliplatin for Injection may cause fertility problems in males and females. Talk to your doctor if this is a concern for you.
    • are breastfeeding or plan to breastfeed. It is not known if oxaliplatin passes into your breast milk. Do not breastfeed during treatment with Oxaliplatin for Injection and for 3 months after the final dose.

    Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.

    How will I receive Oxaliplatin for Injection?

    • Oxaliplatin for Injection is given to you into your vein through an intravenous (IV) tube.
    • Your doctor will prescribe Oxaliplatin for Injection in a dose that is right for you.
    • Your doctor may change how often you receive Oxaliplatin for Injection, your dose, or how long your infusion will take.
    • You and your doctor will decide how many Oxaliplatin for Injection treatments you will receive.
    • It is very important that you do exactly what your doctor and nurse tell you to do.
    • Some medicines may be given to you before Oxaliplatin for Injection to help prevent nausea and vomiting.
    • Each treatment course is given to you over 2 days. You will receive Oxaliplatin for Injection on the first day only.
    • There are usually 14 days between each chemotherapy treatment course.
    • It is important for you to keep all of your medical appointments. Call your doctor if you miss an appointment. There may be special instructions for you.

    Treatment Day 1:

    • Oxaliplatin for Injection and leucovorin will be given through a thin plastic tube into a vein (intravenous infusion or IV) and given for 2 hours. You will be watched by a healthcare provider during this time.
    • Right after the Oxaliplatin for Injection and leucovorin are given, 2 doses of fluorouracil will be given. The first dose is given right away into your IV tube. The second dose will be given into your IV tube over the next 22 hours, using a pump device.

    Treatment Day 2:

    You will not get Oxaliplatin for Injection on Day 2. Leucovorin and fluorouracil will be given the same way as on Day 1.

    The fluorouracil will be given through your IV with a pump. If you have any problems with the pump or the tube, call your doctor, your nurse, or the person who is responsible for your pump. Do not let anyone other than a healthcare provider touch your infusion pump or tubing.

    What should I avoid while receiving Oxaliplatin for Injection?

    • Avoid cold temperatures and cold objects. Cover your skin if you go outdoors in cold temperatures.
    • Do not drink cold drinks or use ice cubes in drinks.
    • Do not put ice or ice packs on your body.
    • Oxaliplatin for Injection can cause dizziness, vision problems, or vision loss that can affect your ability to drive or use machines. You should not drive or operate machinery if you develop these symptoms while receiving Oxaliplatin for Injection.

    See “How can I reduce the side effects caused by cold temperatures?” for more information.

    Talk with your doctor and nurse about your level of activity during treatment with Oxaliplatin for Injection. Follow their instructions.

    What are the possible side effects of Oxaliplatin for Injection?

    Oxaliplatin for Injection can cause serious side effects, including:

    • See “What is the most important information I should know about Oxaliplatin for Injection?”
    • Nerve problems. Oxaliplatin for Injection can affect how your nerves work and make you feel. Nerve problems may happen with the first treatment or within two days after your treatment of Oxaliplatin for Injection. Nerve problems may last a short time (acute) or may become persistent. Symptoms may improve after stopping treatment with Oxaliplatin for Injection. Exposure to cold or cold objects may cause or worsen nerve problems. Tell your doctor right away if you get any signs of nerve problems, including:
      • very sensitive to cold temperatures and cold objects
      • trouble breathing, swallowing, or saying words, jaw tightness, odd feelings in your tongue, or chest pressure
      • pain, tingling, burning (pins and needles, numb feeling) in your hands, feet, or around your mouth or throat, which may cause problems walking, fall, or performing activities of daily living.

    For information on ways to lessen or help with the nerve problems, see the end of this leaflet, “How can I reduce the side effects caused by cold temperatures?”

    • Posterior Reversible Encephalopathy Syndrome (PRES). PRES is a rare condition that affects the brain. Tell your doctor right away if you have any of the following signs and symptoms of PRES:
      • headache
      • confusion or a change in the way you think
      • seizures
      • vision problems, such as blurriness or vision loss
    • Low blood cell counts (myelosuppression). Oxaliplatin for Injection when used with fluorouracil and leucovorin can cause low blood cells counts. Low blood cell counts are common with Oxaliplatin for Injection when used with fluorouracil and leucovorin and can lead to serious infection and death. Tell your doctor right away if you have a fever greater than 100.9°F (38.3°C) or a prolonged fever greater than 100.4°F (38°C) for more than one hour (febrile neutropenia). Call your doctor right away if you get any of the following signs of infection:
    • Risk of new cancers. Leukemia, a form of blood cancer, has been reported in patients after taking Oxaliplatin for Injection in combination with certain other medicines. Talk to your doctor about the potential for increased risk of this type of cancer when taking Oxaliplatin for Injection and certain other medicines.
    • Lung Problems. Oxaliplatin for Injection can cause lung problems that may lead to death. Tell your doctor right away if you get any of the following symptoms as these may be indicators of a serious lung disease:
    • shortness of breath
    • wheezing
    • cough
    • Liver problems (hepatotoxicity). Your doctor will do blood tests to check your liver when you start receiving Oxaliplatin for Injection, and before each treatment course as needed.
    • Heart problems. Oxaliplatin for Injection can cause heart problems that have led to death. Your doctor may do blood and heart tests during treatment with Oxaliplatin for Injection if you have certain heart problems. If you faint (lose consciousness) or have an irregular heartbeat or chest pain during treatment with Oxaliplatin for Injection, get medical help right away as this may be a sign of a serious heart condition. 
    • Muscle problems. Oxaliplatin for Injection can cause muscle damage (rhabdomyolysis) which can lead to death. Tell your doctor right away if you have muscle pain and swelling, along with weakness, fever, or red-brown urine.
    • Harm to an unborn baby. See “What should I tell my doctor before receiving Oxaliplatin for Injection?”
    • Bleeding problems (hemorrhage). Oxaliplatin for Injection when used with fluorouracil and leucovorin can cause bleeding problems (hemorrhage) that can lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs or symptoms of bleeding, including:

    • blood in your stools or black stools
      (looks like tar)
    • increased bruising
    • dizziness
    • pink or brown urine
    • weakness
    • unexpected bleeding, or bleeding that is severe or you cannot control
    • confusion
    • changes in speech
    • vomit blood or vomit that looks like coffee grounds
    • headache that lasts a long time
    • cough up blood or blood clots

    The most common side effects of Oxaliplatin for Injection include:

    • numbness, pain, tingling, and/or burning along the nerves
    • low white blood cells (blood cells important for fighting infection)
    • low platelet count (important for clotting and to control bleeding)
    • low red blood cells (blood cells that carry oxygen to the tissues)
    • nausea
    • changes in liver function tests
    • diarrhea
    • vomiting
    • tiredness
    • mouth sores

    Tell your doctor if you have any side effect that bothers your or that does not go away. These are not all the possible side effects of Oxaliplatin for Injection. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    How can I reduce the side effects caused by cold temperatures?

    • Cover yourself with a blanket while you are getting your Oxaliplatin for Injection infusion.
    • Do not breathe deeply when exposed to cold air.
    • Wear warm clothing in cold weather at all times. Cover your mouth and nose with a scarf or a pull-down cap (ski cap) to warm the air that goes to your lungs.
    • Wear gloves when taking things from the freezer or refrigerator.
    • Drink fluids warm or at room temperature.
    • Always drink through a straw.
    • Do not use ice chips if you have nausea or mouth sores. Ask your doctor about what you can use.
    • Be aware that most metals are cold to touch, especially in the winter. These include your car door and mailbox. Wear gloves to touch cold objects.
    • Do not run the air-conditioning at high levels in the house or in the car in hot weather.
    • If your body gets cold, warm-up the affected part. If your hands get cold, wash them with warm water.
    • Always let your doctor know before your next treatment how well you did since your last visit.

    Your doctor may have other useful tips for helping you with side effects.

    General information about the safe and effective use of Oxaliplatin for Injection

    Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. This Patient Information leaflet summarizes the most important information about Oxaliplatin for Injection. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Oxaliplatin for Injection that is written for health professionals.

    What are the ingredients in Oxaliplatin for Injection?
    Active ingredient:
    oxaliplatin, USP
    Inactive ingredients: lactose monohydrate

    Manufactured by: Sindan Pharma SRL, 11 Ion Mihalache Blvd, Bucharest 1, Romania 011171

    Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054 USA

    For more information, call 1-888-838-2872.

    This Patient Information has been approved by the U.S. Food and Drug Administration.             Rev. B 10/2020

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Actavis

    NDC 45963-611-53

    Oxaliplatin for Injection, USP

    50 mg vial

    Lyophilized Powder for reconstitution

    Must be diluted.
    See package insert for further
    required reconstitution and dilution.
    DO NOT MIX OR ADD SODIUM
    CHLORIDE-CONTAINING SOLUTIONS

    For Intravenous Use Only

    CAUTION: Cytotoxic Agent

    Single-Dose Vial1

  • INGREDIENTS AND APPEARANCE
    OXALIPLATIN 
    oxaliplatin injection, powder, lyophilized, for solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:45963-611
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    OXALIPLATIN (UNII: 04ZR38536J) (OXALIPLATIN - UNII:04ZR38536J) OXALIPLATIN5 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:45963-611-531 in 1 CARTON01/05/2015
    110 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    2NDC:45963-611-591 in 1 CARTON01/05/2015
    220 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA07880301/05/2015
    Labeler - Actavis Pharma, Inc. (119723554)